Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Core Insights - Prime Medicine is advancing its pipeline with new preclinical data for PM577 in Wilson's Disease and has nominated PM647 for Alpha-1 Antitrypsin Deficiency, with both expected to file IND and/or CTA applications in the coming years [1][2][3] Pipeline Developments - The company is focused on liver-targeted programs for Wilson's Disease and Alpha-1 Antitrypsin Deficiency, with IND filings anticipated in H1 2026 for AATD and H1 2027 for WD, and initial clinical data expected in 2027 [3][4] - Prime Medicine is also developing a Cystic Fibrosis program and exploring collaborations, including a partnership with Bristol Myers Squibb for Prime Edited CAR-T products [4][11] Leadership and Corporate Updates - Matthew Hawryluk, Ph.D., M.B.A., has been appointed as Chief Business Officer to enhance business development and strategic collaborations [1][10] - A virtual KOL event is scheduled for November 12, 2025, to discuss the company's strategy for Wilson's Disease [1][10] Financial Performance - For Q3 2025, Prime Medicine reported R&D expenses of $44.0 million, up from $40.3 million in Q3 2024, primarily due to increased license and intellectual property costs [10][20] - General and Administrative expenses decreased to $11.2 million from $14.1 million year-over-year, attributed to workforce reductions [10][20] - The net loss for Q3 2025 was $50.6 million, slightly improved from a net loss of $52.5 million in Q3 2024 [10][20] - As of September 30, 2025, the company had cash and investments totaling $213.3 million, sufficient to fund operations into 2027 [8][18]